Introduction
Eosinophilic oesophagitis (EoE) is a chronic inflammatory disease of the oesophagus characterised clinically by symptoms of esophageal dysfunction and histopathologically by a prominent eosinophilic inflammation. EoE has a rapidly increasing incidence and prevalence in westernised areas. 1 If left untreated, eosinophilic inflammation induces oesophageal remodelling with fibrosis and stricture formation, resulting finally in a morphological and functional damage of the organ. In addition, uncontrolled eosinophilic inflammation is a permanent risk for experiencing food impactions. 2, 3 It is therefore accepted widely that active EoE should be treated. 4, 5 Among the pharmacological options, only corticosteroids have documented efficacy, and swallowed topical corticosteroids are established as first-line drugs in the treatment of active EoE. 4, 6 Unfortunately, the therapeutic goals cannot often be achieved, as corticosteroid resistance occurs in up to 50% of the patients. 4, 6 For these resistant patients, there is a need for alternative treatment options.
The presence of eosinophils in oesophageal epithelium is the hallmark of EoE, and more than 15 eosinophils per high-power field (HPF) corroborate the diagnosis of active EoE. Of note, so far diagnosis and determination of inflammatory activity are based almost exclusively on the assessment of epithelial alterations. Recently new endoscopic sampling techniques have been developed allowing collecting subepithelial tissue in a representative amount. This enables characterisation of the histological alterations occurring in the subepithelial compartment of the oesophageal wall. 7 Besides eosinophils, gene expression studies revealed a strong type 2 immune response in EoE, with mast cells as potential key regulators of EoE pathology. 8, 9 The prevalence of the type 2 immunity pathway provided hope for anti-type 2 immunity therapeutics such as anti-interleukin (IL)-5, anti-IL-13 and chemoattractant receptor-homologous molecule expressed on T helper type 2 (CRTH2) antagonists. Although proof-of-concept studies with anti-type 2 immunity treatments showed consistent reduction of eosinophils in tissue, overall clinical effects were modest. [10] [11] [12] Of interest was the observation that paediatric patients, who benefited from anti-IL-5 treatment, showed a reduction of oesophageal eosinophils together with a reduced number of oesophageal mast cells, pointing towards a potential responder patient subgroup. 13 Human mast cells contain two types of serine proteases, tryptase and chymase. Mast cells are divided into two groups; some mast cells are tryptase-positive (MC T ) and the other group contains both tryptase and chymase (MC TC ).
14 The different mast cell phenotypes, and in particular the chymase-positive mast cells, were reported to be linked to corticosteroid resistance and a more severe disease manifestation in asthma patients. 15 So far, the chymase-positive mast cells were not studied in EoE patients to the same extent as the total mast cells.
In summary, while epithelial eosinophils are assessed routinely in EoE as diagnostic and disease activity markers, mast cells are evolving as an important factor.
The purpose of this study was therefore to characterise the epithelial and subepithelial mast cell infiltration and to clarify their immune-pathogenic role and the resulting clinical consequences in this chronic inflammatory condition.
Methods

S U B J E C T S E L E C T I O N A N D D E F I N I T I O N S
The Swiss EoE Registry was founded in 1989 and consists of a database and a biobank. This Registry was approved by the Ethical Committee of Kanton Aargau/Solothurn. It currently contains data sets from 947 EoE patients, as well as oesophageal biopsies from 388 EoE patients and 90 healthy controls. Criteria for inclusion in the Registry are, first, a confirmed diagnosis of EoE according to the consensus recommendations (for patients), 6 and secondly, written informed consent signed by participants. From this depository, 53 paraffin-embedded and RNAlaterfixed tissue specimens from patients with active, remission and corticosteroid-resistant EoE, as well as from healthy controls were used.
Active EoE was defined as having symptoms of oesophageal dysfunction, endoscopic signs of active eosinophilic inflammation such as oedema, furrows, white exudates (optional) and >15 eosinophils/HPF in the oesophageal biopsies. EoE in remission was defined as the absence of EoE-attributed symptoms at the time of examination, no signs endoscopically of active eosinophilic inflammation and ≤5 eosinophils/HPF on histology samples. Corticosteroid-resistant EoE patients were defined as those having EoE-attributed symptoms, endoscopic signs of active eosinophilic inflammation and >15 eosinophils/HPF, despite correctly performed treatment with swallowed topical corticosteroids ≥0.5 mg twice daily during the 3 months prior to examination. Control subjects were defined by the absence of oesophageal-attributed symptoms and history of EoE and having normal endoscopic findings and normal oesophageal histology with <5 eosinophils/ HPF.
For diagnosis, all oesophageal biopsies were evaluated by an EoE expert pathologist (C.B.). Eosinophils were identified by haemotoxylin and eosin (H&E) staining. Eosinophils in the most densely infiltrated areas were counted in five consecutive HPFs (Zeiss Axiophot, Plan-Neofluar 40, ocular magnification 910, area of microscopic field 0.3072 mm
Stainings of 4 lm paraffin sections were performed using the Leica Bond Max (Leica Biosystems, Muttenz, Switzerland) automated stainer with an optimised staining protocol. Eosinophil cationic protein (ECP)-RNAse3 antibody (LS-B12766; LifeSpan BioScience, Inc., Seattle, WA, USA) was used to stain eosinophils and the Bond Polymer Refine Red Detection Kit was used for secondary antibody and colour development (DS9390; Leica Biosystems). Chymase and tryptase antibodies (respectively, ab2377; Abcam, Cambridge, UK and M7052; Dako, Santa Clara, CA, USA) were used for mast cell staining and anti-epithelial membrane antigen (EMA) antibody for epithelial cell staining (Leica Novacastra). Alexa Fluor 568 donkey anti-mouse antibody (Invitrogen TM, Life Technologies, Zug, Switzerland) and Alexa Fluor 488 donkey anti-rabbit (Invitrogen TM) were used as secondary antibodies.
I M A G E A C Q U I S I T I O N A N D I M A G E A N A L Y S I S
Immunohistochemistry slides were scanned using the Nanozoomer whole slide scanner (Hamamatsu Photonics, Solothurn, Switzerland) at 940 magnification for single-cell identification. Images were uploaded onto the ORBIT image analysis platform (http://www. orbit.bio; Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland). The epithelial layer was identified by EMA staining, the underneath layer was identified as lamina propria and both layers were delineated manually as regions of interest 1 and 2 (ROI1-ROI2). Tissue classification was performed to quantify ECP staining per mm 2 of each ROI. Cell segmentation was performed on the chymase and tryptase staining to determine the number of mast cells per mm 2 of epithelial and subepithelial tissue.
S T A T I S T I C A L A N A L Y S I S
Data analyses were performed using R version 3.3.3. 16 Spearman's rank correlation coefficient was used to describe the relationship between variables and P-values were adjusted using the BenjaminiHochberg procedure to control the false discovery rate at level 0.05.
Patients were grouped using an agglomerative hierarchical clustering; splits in the hierarchical tree were defined using Euclidean distance and Ward's linkage criterion. All authors had access to the study data and had reviewed and approved the final manuscript.
Results
Tissue specimens from a total of 53 individuals were included in this analysis. Sixteen patients (aged 20-67 years; 12 males) had active EoE at the time of examination. Of these, eight received no treatment, six had active disease despite ongoing treatment (with swallowed topical corticosteroids) and two were under proton pump inhibitor (PPI) monotherapy. Twenty-five EoE patients (aged 17-81 years; 17 males) were in remission at the time of examination. Sixteen of these patients were under treatment with swallowed topical corticosteroids, five were treated with a combination of swallowed topical corticosteroids and PPI, two were under PPI monotherapy and two had spontaneous remission without any medication. To compare the findings to non-inflamed conditions, oesophageal tissues samples from 12 healthy individuals (aged 20-79 years; five males) were included.
The oesophageal tissue architecture consists of an epithelial and a lamina propria layer followed by submucosa and muscularis ( Figure 1A ). Biopsies are taken endoscopically for diagnosis of EoE and to follow disease activity, and by using forceps both epithelium and lamina propria can be obtained. Tissue sections stained with H&E ( Figure 1B ) and EMA ( Figure 1C ) identified the tissue architecture of the biopsies. In 90% of EoE patients with active disease or in clinical remission both the epithelial and subepithelial layers were obtained ( Figure 1D ). In contrast, in healthy controls only 30% of the biopsies contained subepithelial material in a representative amount, providing a potential bias in the analysis of tissue homogenates which do not take the tissue architecture into account.
Epithelial eosinophils were either counted by an experienced pathologist in H&E stainings or quantified using ECP as eosinophil-specific marker. ECP-positive tissue was detected using an automated algorithm that allowed quantifying ECP separately, both in the epithelium and the lamina propria (Figure 2A ). Eosinophils were not counted as individual cells but rather as positive areas, as ECP protein can be retained by eosinophils or degranulated inside tissue. Epithelial eosinophils counted by H&E, considered as the gold standard, correlated well with the automated quantification of epithelial ECP-positive eosinophils (r = 0.805, P < 0.001) and subepithelial ECP-positive eosinophils (r = 0.721, P < 0.001).
Eosinophils were compared between the patient groups and healthy controls and evaluated for correlation in the two different tissue compartments (Figure 2B) . As it is part of the diagnosis of active EoE, epithelial eosinophils only increased in patients with active disease. Eosinophils increased both in the epithelium and submucosa, showing cross-tissue compartment localisation. Epithelial and subepithelial ECP-positive eosinophils correlated well (r = 0.728, P < 0.001).
Mast cells stained well in the biopsies using both chymase and tryptase as mast cell-specific markers. Mast cells were counted separately in the epithelium and the lamina propria using an automated algorithm ( Figure 3A) . Both epithelial and subepithelial tryptase-and chymase-positive mast cells correlated well (r = 0.678 and 0.745, P < 0.001 and <0.001, respectively).
Mast cells were compared between the patient groups and healthy controls and evaluated for correlation in the different tissue compartments (Figure 3B) . Both chymase-and tryptase-positive mast cells were increased in the epithelium compared to healthy controls (seven-and 2.25-fold, P = 0.0002 and 0.0015, respectively). Of note, also in patients in clinical remission, an elevated number of mast cells was observed compared to controls (1.5 and twofold). In contrast to the epithelium, chymase-and tryptasepositive mast cells were decreased in the lamina propria of active-EOE patients versus control (3.1-and 2.7-fold, respectively). There was no correlation between the mast cells across the epithelium and the lamina propria.
To allow for an unbiased patient characterisation based on epithelial eosinophils and mast cells, a clustering analysis was conducted (Figure 4 ). Patients were subjected to two main clusters separated by healthy controls (cluster A) and active EoE disease (cluster B). Most of the patients in clinical remission (18) were grouped in cluster A with the healthy controls. In addition, one patient with active EoE was grouped in cluster A. In cluster B, six patients in clinical remission and one healthy control clustered with the active EoE patients. Evaluation of the two different types of EoE patients in remission demonstrated that there was no difference in terms of eosinophils, but a clear separation based on tryptase-and chymase-positive mast cells independent of their treatment modality (Figure 5) . The six patients in clinical remission who clustered with the active EoE patients all showed an increased number of epithelial mast cells, comparable to patients with active EoE. 
Discussion
Eosinophilic oesophagitis (EoE) is a rapidly evolving chronic inflammatory disease of the oesophagus. In routine diagnosis, epithelial eosinophils are assessed quantitatively and diagnosis, as well as disease activity, is based mainly on epithelial eosinophil numbers. Today it is undisputed that this inflammatory condition should be treated. 17 Although topically administered corticosteroids are used widely, no drug is officially approved. Unfortunately, steroid resistance occurs frequently and therapeutic alternatives are therefore needed urgently. 18 Preliminary results have shown that blocking pathways linked to type 2 immunity could represent an alternative to the established treatment with corticosteroids. [10] [11] [12] Next to eosinophils, mast cells play an important role in driving chronic allergic diseases for type 2 cell-mediated immunity. 19 Mast cells are key players that react to an immunoglobulin (Ig)E-mediated allergic response that leads to inflammation, e.g. in asthma patients. 19 Despite it being well established that mast cells are important in many type 2 immunity diseases, the role of these inflammatory cells and the interplay with other cells, such as eosinophils, is not understood fully. Focusing exclusively on epithelial eosinophilia Hierarchical clustering tree separating patients and controls based on automated counting of epithelial mast cells and eosinophils. Patients were grouped using an agglomerative hierarchical clustering, and splits in the hierarchical tree were defined using Euclidean distance and Ward's linkage criterion. Two clear clusters of patients can be identified: cluster A enclosing most patients with active eosinophilic oesophagitis (EoE) and six patients with EoE in clinical remission; and cluster B with most control subjects and the majority of patients in clinical remission. might therefore be too narrow an approach in EoE, first because mast cells probably also play a relevant role, and secondly because in EoE the inflammatory response is not restricted to the epithelium. 8, 9 In our study, an almost identical increase of epithelial tryptase-and chymase-positive mast cell numbers was observed in EoE patients with active disease compared to control patients. An additional important observation was the decrease of mast cell numbers in the subepithelial compartment. Mast cells were stained both for chymase and tryptase to investigate different mast cell phenotypes that were described previously in, for example, asthma patients. 14, 15 Furthermore, our results demonstrate that in EoE the eosinophilic inflammation is not limited to the epithelium, but to the same extent also shows infiltration of eosinophils in the subepithelial. This contrasts with the localised increase of mast cells in the epithelium. It is therefore likely that eosinophils show a more generalised infiltration compared to the mast cells that increase locally in the epithelium in active disease. We used automated quantification of stained eosinophils in the epithelium and in the subepithelial compartment. We showed that automated quantification of ECP in the epithelium provided a similar picture to the counting of epithelial eosinophils by an expert pathologist using H&E staining. In addition, image analysis allowed separating and quantifying the proportion of infiltrated eosinophils in the epithelium versus the subepithelial compartment.
To our surprise, we observed a remaining high number of chymase-and tryptase-positive mast cells in a substantial subset of EoE patients in clinical and histological remission. Based on our findings, we ran a clustering analysis with the mast cell and eosinophil numbers in the epithelium. The cluster analysis separated well between the patients with active disease and the healthy controls. In addition, patients in remission were separated into two groups driven only by the difference in epithelial mast cell numbers. Previous animal model studies showed that mast cells precede the infiltration of tissue by eosinophils. 20, 21 The significance of these remaining mast cells in patients with EoE in remission needs further investigation, but it can be hypothesised that those mast cells might play a role in relapses. Although no double stainings were performed, our results suggest a predominant MC TC mast cell phenotype in EoE. Whereas tryptase-positive mast cells were described previously in EoE, 8 chymase-positive mast cells were not investigated in EoE. Overall, very little is known concerning the different mast cell phenotypes, but chymase-positive mast cells are of particular importance because of the potential corticosteroid resistance 22 and their link to a more severe disease in asthma patients. 14 A strength of this study was the histological evaluation of the biopsy architecture which revealed a disease bias, that was more likely to obtain subepithelial material when taking biopsy samples from EoE patients with active disease and in clinical remission compared to healthy controls. It is possible that the ongoing or previous inflammation affected the tissue integrity causing such a bias. In the case of histological analysis this bias is of no concern, but when using technologies that are blind to biopsy architecture, a potential sampling bias artefact cannot be ruled out. This study suffers from the small patient group size, aggravated by the observation of novel patient subgroups, and therefore needs replication in a larger cohort.
In summary, this study confirms that eosinophils and mast cells are involved in the inflammatory response of EoE, but that the mast cell infiltration is confined to the epithelium whereas, in addition, eosinophils infiltrate the subepithelial tissue of the oesophageal wall. Moreover, it identifies patients in clinical remission who show residual high numbers of mast cells despite the absence of eosinophils. The consequence of these mast cells remains to be investigated in longitudinal studies with larger patient cohorts.
